5.2 Generic Substitution, Bioequivalence, & Orange Book

5.2 Generic Substitution, Bioequivalence, & Orange Book

California Generic Substitution Law

California law places a strong emphasis on reducing healthcare costs for patients by mandating generic substitution where appropriate. Under California Business and Professions Code (B&P) § 4073, a pharmacist filling a prescription order for a drug product prescribed by its trade or brand name must select another drug product with the same active chemical ingredients of the same strength, quantity, and dosage form, and of the same generic drug name as determined by the United States Adopted Names (USAN) and accepted by the FDA.

The substitution is only permitted if the generic drug will cost the patient less than the prescribed brand-name drug. The pharmacist must inform the patient of the substitution.

Exceptions to Mandatory Substitution

A pharmacist cannot substitute a generic drug if one of the following conditions is met:

1. Prescriber Directive: The prescriber indicates, either orally or in writing, that no substitution is permitted. On a written prescription, this is typically done by writing "Do Not Substitute" (DNS) or checking a "Dispense As Written" (DAW) box. Notably, California law prohibits pre-printed "Do Not Substitute" checkboxes; the prescriber must personally check or initial the box.
2. Patient Request: The patient explicitly requests the brand-name drug.
3. Cost Factor: The generic drug does not result in a lower cost to the patient.

If the pharmacist does dispense the generic equivalent, they must indicate on the prescription label the generic name and the manufacturer of the drug dispensed. Furthermore, the label must state the generic name followed by the phrase "generic for" and the brand name of the drug prescribed (e.g., "Atorvastatin generic for Lipitor").

The mandate for generic substitution plays an outsized role in the economics of pharmacy and the broader healthcare system. Without such laws, brand name manufacturers could indefinitely retain market share long after their patents expire. Pharmacies serve as the vital linchpin in this system, ensuring that patients receive affordable, safe, and effective equivalent treatments. The communication with the patient during the counseling phase is particularly critical here. Pharmacists should thoroughly explain that the active ingredient is identical, thus preventing patient confusion and fostering adherence.

FDA Orange Book and Bioequivalence Ratings

When a pharmacist makes a substitution, they must ensure the substituted product is therapeutically equivalent. The primary resource for determining this is the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.

The Orange Book assigns a two-letter coding system to evaluate therapeutic equivalence:

• "A" Rated Products: Drug products that the FDA considers to be therapeutically equivalent to other pharmaceutically equivalent products. These are products for which there are no known or suspected bioequivalence problems, or actual/potential bioequivalence problems have been resolved with adequate in vivo and/or in vitro evidence supporting bioequivalence.
  • AB: Products meeting necessary bioequivalence requirements.
  • AA: Products in conventional dosage forms not presenting bioequivalence problems.
  • AN: Solutions and powders for aerosolization.
  • AO: Injectable oil solutions.
  • AP: Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions.
  • AT: Topical products.
• "B" Rated Products: Drug products that the FDA at this time considers not to be therapeutically equivalent to other pharmaceutically equivalent products. A "B" rating indicates that the FDA has documented bioequivalence problems or significant potential for such problems, and no adequate studies have proven bioequivalence. Under California law, a pharmacist should generally not substitute a "B" rated product for a prescribed drug without consulting the prescriber.

Pharmacists must develop a strong intuition for navigating the Orange Book, particularly when dealing with complex dosage forms or modified-release formulations. Sometimes a generic product is only rated AB1 or AB2 to a specific brand-name drug, indicating that it is therapeutically equivalent only to a particular reference listed drug (RLD) and not to all other drugs containing the same active ingredient. Such nuanced evaluations are part of the critical professional judgment pharmacists exercise daily.

Biological Products and Biosimilars (The Purple Book)

Biological products (biologics) are complex molecules produced from living organisms. Because of their complexity, they cannot be copied exactly like traditional small-molecule generic drugs. Instead, manufacturers develop "biosimilars."

A biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product. An interchangeable biosimilar is a biosimilar that meets additional requirements and may be substituted for the reference product at the pharmacy without the intervention of the prescriber.

The FDA's Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilar or Interchangeable Evaluations, commonly known as the Purple Book, is the equivalent resource to the Orange Book for biological products.

Substitution Rules for Biologics (B&P § 4073.5)

Under California B&P § 4073.5, a pharmacist may substitute an interchangeable biological product for a prescribed reference product if all the following apply:

1. The FDA has determined the product to be "interchangeable" with the prescribed biological product.
2. The prescriber does not personally indicate "Do Not Substitute" (or similar directive) on the prescription.
3. The patient does not refuse the substitution.
4. The substitution results in a lower cost to the patient.

Crucial Communication Requirement: Unlike traditional generic substitutions, if a pharmacist substitutes an interchangeable biological product, the pharmacy must communicate to the prescriber the specific product provided to the patient, including the name of the product and its manufacturer. This communication must occur within five (5) business days of dispensing the biological product. The communication can be made via an interoperable electronic medical records system, electronic prescribing technology, a pharmacy benefit management system, or a pharmacy record that the prescriber can access electronically. If these electronic systems are unavailable, facsimile, telephone, or electronic transmission is acceptable.

Understanding these substitution laws is vital for California pharmacists, as it balances the need to provide cost-effective care with the absolute necessity of maintaining therapeutic safety and efficacy. In cases of interchangeable biosimilars, the required communication loop ensures the prescribing physician maintains full visibility over the patient's exact treatment.